Metformin and Anesthesia: Perioperative Interaction Guide

Is there a direct interaction between metformin and anesthetic drugs?

The label's drug interaction table names carbonic anhydrase inhibitors, drugs that reduce metformin clearance (ranolazine, vandetanib, dolutegravir, cimetidine), alcohol, insulin and insulin secretagogues, and drugs that tend to raise blood glucose [1]. Anesthetic agents are not among them. The label states that metformin is not metabolized, is negligibly bound to plasma proteins and is cleared by the kidneys [1].

The label's perioperative statement is indirect: withholding food and fluids during surgical or other procedures may increase the risk of volume depletion, hypotension and renal impairment [1]. Metformin's plasma half-life is about 6.2 hours, renal clearance is roughly 3.5 times creatinine clearance, and half-life lengthens as kidney function falls [1]. The label says the risk of metformin accumulation rises with the severity of renal impairment, because metformin is substantially excreted by the kidney [1].

What the label says about surgery

The metformin hydrochloride tablets label lists surgery and other procedures among the risk factors for metformin-associated lactic acidosis in its boxed warning, alongside renal impairment, certain interacting drugs such as topiramate, age 65 or older, radiological studies with contrast, hypoxic states such as acute heart failure, excessive alcohol intake, hepatic impairment and mitochondrial disease [1].

The surgical instruction is short: the label says metformin should be temporarily discontinued while patients have restricted food and fluid intake [1]. The hold is tied to the period of restricted intake. The one explicit time window the label gives is in the contrast rule, below [1].

The label says to check eGFR before metformin is started and at least yearly afterwards, and to assess renal function more often in people at risk of renal decline, such as the elderly [1].

Iodinated contrast during or around surgery

The label states that giving intravascular iodinated contrast to metformin-treated patients has led to an acute decrease in renal function and to lactic acidosis [1]. It says to stop metformin at the time of, or before, the imaging procedure in three situations: eGFR between 30 and 60 mL/min/1.73 m²; a history of hepatic impairment, alcoholism or heart failure; or planned intra-arterial contrast [1]. eGFR is rechecked 48 hours after the procedure, and metformin is restarted if renal function is stable [1].

The intra-arterial criterion is listed as its own situation, separate from the eGFR range [1].

Kidney thresholds that matter before and after an operation

• Metformin is contraindicated at an eGFR below 30 mL/min/1.73 m² [1].
• Starting metformin is not recommended at an eGFR of 30 to 45 mL/min/1.73 m² [1].
• If eGFR later falls below 45, the label says to reassess the benefit and risk of continuing; it should be discontinued if eGFR falls below 30 [1].

Other labeled interactions that can surface around an operation

• Carbonic anhydrase inhibitors such as topiramate, zonisamide, acetazolamide and dichlorphenamide lower serum bicarbonate, can produce a non-anion gap acidosis and may increase lactic acidosis risk; the label says to consider more frequent monitoring when metformin is used with these drugs [1].
• Drugs that block renal tubular transport of metformin (OCT2 and MATE inhibitors) raise metformin exposure, and the label names ranolazine, vandetanib, dolutegravir and cimetidine, asking that benefits and risks be weighed [1].
• Insulin and insulin secretagogues raise the risk of hypoglycemia, and the label notes that lower doses of either may be required [1].
• Drugs that push glucose up, including thiazides and other diuretics, corticosteroids, sympathomimetics and calcium channel blockers, can cause loss of glycemic control, and the label asks for close observation [1].
• Alcohol: the label states that alcohol potentiates the effect of metformin on lactate metabolism and warns against excessive alcohol intake [1].

What lactic acidosis looks like

The boxed warning describes a subtle onset with nonspecific symptoms: malaise, myalgias, respiratory distress, somnolence and abdominal pain, with hypothermia, hypotension and resistant bradyarrhythmias in severe cases [1]. The laboratory picture is a blood lactate above 5 mmol/L, an anion gap acidosis and metformin plasma levels generally above 5 mcg/mL [1].

If metformin-associated lactic acidosis is suspected, the label says to discontinue metformin and institute general supportive measures in a hospital setting, with prompt hemodialysis recommended; metformin is dialyzable with a clearance of up to 170 mL/min under good hemodynamic conditions, and dialysis has often reversed the symptoms [1]. A 2015 Extracorporeal Treatments in Poisoning systematic review recommends extracorporeal treatment for severe metformin poisoning, with indications including lactate above 20 mmol/L, pH of 7.0 or lower, shock, failure of standard supportive measures and decreased consciousness; treatment continues until lactate is below 3 mmol/L and pH above 7.35, and intermittent hemodialysis is the preferred first method [2]. The same review describes metformin toxicity as associated with a mortality of 30% [2].

Outcomes are serious once acidosis is established. Of 197 patients admitted to one medical ICU with lactic acidosis over a five-year period, 10 had metformin-associated lactic acidosis; their mean lactate was 18.7 mmol/L and median arterial pH 6.78, and mortality was 50%, against 74% in lactic acidosis from other causes [3].

What the studies show about risk overall

A Cochrane systematic review by Salpeter and colleagues, published in 2010, pooled 347 comparative trials and cohort studies in type 2 diabetes and found no cases of fatal or nonfatal lactic acidosis in 70,490 patient-years of metformin use or in 55,451 patient-years of non-metformin treatment; the calculated upper limit of the true incidence was 4.3 cases per 100,000 patient-years with metformin and 5.4 without it [4].

A separate propensity-matched analysis of Taiwan's National Health Insurance Research Database looked at a different outcome. Adults with type 2 diabetes who had coronary artery bypass grafting or valve replacement between 2015 and 2018 had lower odds of postoperative delirium if they used metformin (adjusted odds ratio 0.52, 95% CI 0.40 to 0.67), with a dose-response trend across cumulative exposure [5]. It is an observational association and does not show that metformin prevents, or causes, any perioperative complication.

Restarting metformin after a procedure

The one postoperative checkpoint the label specifies is the contrast rule: recheck eGFR 48 hours after the imaging procedure and restart if renal function is stable [1]. For surgery without contrast, the label's stop instruction is tied to the period of restricted food and fluid intake [1].